ProQR Therapeutics (PRQR) News Today $1.14 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.18 +0.04 (+3.07%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period 2,825,000 Shares in ProQR Therapeutics (NASDAQ:PRQR) Bought by Affinity Asset Advisors LLCAffinity Asset Advisors LLC bought a new stake in ProQR Therapeutics (NASDAQ:PRQR - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,825,000 shares of the biopharmaceutical company's stock, valued at approxiApril 17 at 7:52 AM | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by BrokeragesShares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have received a consensus rating of "Buy" from the six research firms that are currently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a sApril 17 at 2:12 AM | marketbeat.comProQR Therapeutics appoints Hom as CFO, Lopez as CMOApril 14 at 7:52 PM | markets.businessinsider.comProQR Therapeutics N.V.: ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of GrowthApril 14 at 9:50 AM | finanznachrichten.deProQR Therapeutics Names Hom as CFO, Lopez Lopez as Chief Medical OfficerApril 14 at 9:50 AM | marketwatch.comProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of GrowthApril 14 at 7:00 AM | globenewswire.comReviewing Carisma Therapeutics (NASDAQ:CARM) and ProQR Therapeutics (NASDAQ:PRQR)April 13, 2025 | americanbankingnews.comProQR Therapeutics Advances RNA Editing PipelineApril 3, 2025 | tipranks.comFY2025 Earnings Estimate for PRQR Issued By Chardan CapitalProQR Therapeutics (NASDAQ:PRQR - Free Report) - Research analysts at Chardan Capital raised their FY2025 earnings per share estimates for ProQR Therapeutics in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst K. Nakae now expects that the biopharmaMarch 28, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of "Buy" by BrokeragesProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been given a consensus recommendation of "Buy" by the six analysts that are currently covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating tMarch 22, 2025 | marketbeat.comPrivium Fund Management B.V. Decreases Stake in ProQR Therapeutics (NASDAQ:PRQR)Privium Fund Management B.V. reduced its position in ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 11.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,985,633 shares of the biopharmaceutical company's stock after selMarch 20, 2025 | marketbeat.comPlatinum Investment Management Ltd. Purchases Shares of 1,538,247 ProQR Therapeutics (NASDAQ:PRQR)Platinum Investment Management Ltd. purchased a new stake in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,538,247 shares of the biopharmaceutical company's stMarch 20, 2025 | marketbeat.comProQR Therapeutics Full Year 2024 Earnings: Misses ExpectationsMarch 15, 2025 | uk.finance.yahoo.comProQR Therapeutics' (PRQR) Buy Rating Reiterated at Chardan CapitalChardan Capital reiterated a "buy" rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Friday.March 15, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $12.00HC Wainwright lifted their target price on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Friday.March 15, 2025 | marketbeat.comProQR Therapeutics price target raised to $12 from $10 at H.C. WainwrightMarch 14, 2025 | markets.businessinsider.comProQR Therapeutics (NASDAQ:PRQR) Announces Earnings ResultsProQR Therapeutics (NASDAQ:PRQR - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.10). ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%.March 14, 2025 | marketbeat.comProQR Therapeutics N.V.: ProQR Announces Year End 2024 Operating and Financial ResultsMarch 14, 2025 | finanznachrichten.deProQR Therapeutics files to sell 3.52M ordinary shares for holdersMarch 14, 2025 | markets.businessinsider.comProQR Therapeutics Reports 2024 Results and Pipeline ProgressMarch 13, 2025 | tipranks.comProQR Announces Year End 2024 Operating and Financial ResultsMarch 13, 2025 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) Stock Rating Upgraded by CitigroupCitigroup raised shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price target for the company in a research note on Monday.March 10, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Buy at CitigroupCitigroup upgraded ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 target price on the stock in a research report on Monday.March 10, 2025 | marketbeat.comProQR Therapeutics upgraded to Buy from Neutral at CitiMarch 7, 2025 | markets.businessinsider.comProQR Therapeutics (NASDAQ:PRQR) Shares Cross Below Two Hundred Day Moving Average - Here's What HappenedProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell?March 5, 2025 | marketbeat.comProQR Therapeutics (PRQR) Expected to Announce Earnings on WednesdayProQR Therapeutics (NASDAQ:PRQR) will be releasing earnings before the market opens on Wednesday, March 12, Financial Modeling Prep reports.March 5, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from BrokeragesShares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have received an average rating of "Buy" from the six analysts that are covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation oFebruary 25, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Above 50 Day Moving Average - Here's WhyFebruary 20, 2025 | marketbeat.comJones Trading Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Buy RecommendationFebruary 12, 2025 | msn.comJones Trading sets ProQR stock Buy rating, $11 price targetFebruary 11, 2025 | msn.comProQR Therapeutics initiated with a Buy at JonesResearchFebruary 11, 2025 | markets.businessinsider.comProQR Therapeutics N.V.'s (NASDAQ:PRQR) largest shareholders are individual investors with 60% ownership, institutions own 17%February 11, 2025 | finance.yahoo.comProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of "Buy" by BrokeragesShares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have received a consensus recommendation of "Buy" from the six ratings firms that are currently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buyJanuary 31, 2025 | marketbeat.comCantor Fitzgerald Predicts PRQR FY2025 EarningsProQR Therapeutics (NASDAQ:PRQR - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for ProQR Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim expects that the biopharmaceutiJanuary 22, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Short Interest UpdateProQR Therapeutics (NASDAQ:PRQR - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 918,100 shares, an increase of 151.7% from the December 15th total of 364,700 shares. Based on an average daily trading volume, of 1,520,000 shares, the days-to-cover ratio is currently 0.6 days.January 14, 2025 | marketbeat.comProQR’s Strategic Focus on RNA Editing for Liver Disease: Targeting PNPLA3 in the MASH SpaceJanuary 13, 2025 | markets.businessinsider.comProQR Therapeutics initiated with an Outperform at OppenheimerJanuary 10, 2025 | markets.businessinsider.comOppenheimer Begins Coverage on ProQR Therapeutics (NASDAQ:PRQR)Oppenheimer assumed coverage on ProQR Therapeutics in a research report on Friday. They set an "outperform" rating and a $15.00 target price for the company.January 10, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by AnalystsProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been given an average rating of "Buy" by the five analysts that are currently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the coJanuary 6, 2025 | marketbeat.comJMP Securities Reiterates "Market Outperform" Rating for ProQR Therapeutics (NASDAQ:PRQR)JMP Securities restated a "market outperform" rating and set a $8.00 price objective on shares of ProQR Therapeutics in a report on Thursday.December 12, 2024 | marketbeat.comProQR Therapeutics' (PRQR) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of ProQR Therapeutics in a research report on Thursday.December 12, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Buy Rating at Chardan CapitalChardan Capital reaffirmed a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a research report on Thursday.December 12, 2024 | marketbeat.comProQR’s Promising RNA-Editing Advancements and Strategic Collaborations Drive Buy RatingDecember 12, 2024 | markets.businessinsider.comProQR Therapeutics announces $8.1M in new funding from RSRTDecember 12, 2024 | markets.businessinsider.comProQR Therapeutics Advances Axiomer RNA-Editing Platform with Strategic PartnershipsDecember 11, 2024 | tipranks.comProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing CollaborationDecember 11, 2024 | markets.businessinsider.comProQR Therapeutics appoints Beal as Chief ADAR ScientistDecember 10, 2024 | tipranks.comProQR Appoints Peter A. Beal, PhD, as Chief ADAR ScientistDecember 10, 2024 | globenewswire.comProQR Therapeutics price target raised to $8 from $5 at JMP SecuritiesDecember 5, 2024 | markets.businessinsider.comProQR Highlights RNA Innovations in Upcoming EventDecember 5, 2024 | tipranks.com Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address PRQR Media Mentions By Week PRQR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRQR News Sentiment▼0.840.80▲Average Medical News Sentiment PRQR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRQR Articles This Week▼81▲PRQR Articles Average Week Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies uniQure News Today Bicycle Therapeutics News Today UroGen Pharma News Today Ginkgo Bioworks News Today GH Research News Today Kura Oncology News Today CorMedix News Today Sage Therapeutics News Today Cullinan Therapeutics News Today Maravai LifeSciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRQR) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRQR Stock Free PRQR Stock Alerts